FDA Division of Bioequivalence Director Dighe
Executive Summary
Detailed to Office of Generic Drugs Director Roger Williams, MD, as his "Senior Advisor with specific responsibility for development of a number of critically important bioequivalence guidances," a Dec. 3 OGD memo states. The detail takes effect Jan. 4 and will extend at least four months. Williams wants to have a senior employee work fulltime on the guidances to make them available sooner to industry. Shrikant Dighe, PhD, will focus on guidelines regarding albuterol metered-dose inhalers, cholestyramine, general bioequivalence, immediate-release formulations, controlled-release formulations and non-fasting drug bioequivalence. Review Branch I Chief Agnes Wu, PhD, will serve as the bioequivalence division's acting director.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth